2. NORMAL OVARIES
• Normal size 5 x 3 x 3cm
• Variation in dimensions can result from
– Endogenous hormonal production(varies with age
and menstrual cycle)
– Exogenous substances, including OCs, GnRH
agonists, or ovulation-inducing medication, may
affect size
5. DIFFERENTIAL DIAGNOSIS OF ADNEXAL MASS
ORGAN CYSTIC SOLID
OVARY Functional cyst, Neoplastic cyst,
Benign, Malignant, Endometriosis
Neoplasm
Benign
Malignant
FALLOPIAN TUBES Tubo-ovarian abscess
Hydrosalpinx
Paraovarian cyst
Tubo-ovarian abscess
Ectopic pregnancy
Neoplasm
UTERUS Intrauterine pregnancy in a bicornuate
uterus
Pedunculated or
inteligamentous myoma
BOWEL Sigmoid or caecum distended with gas
or feces
Diverticulitis, Ileitis,
Appendicitis, Colonic cancer
MISCELLANEOUS Distended bladder, Pelvic kidney,
Urachal cyst
Abdominal wall hematoma or
abscess, retroperitoneal
6. Lifetime Risk of ovarian neoplasm
• A woman has 5–10% lifetime risk of undergoing
surgery for a suspected ovarian neoplasm and
• 13–21% of these will be found to be have an ovarian
malignancy
8. Functional ovarian cysts
• Follicular cysts
• Corpus luteum cysts
• Theca lutein cysts
• Luteomas of pregnancy
By far the most common clinically detectable
enlargements of the ovary in the reproductive years.
All are benign and usually asymptomatic.
12. II. Sex cord tumors:
• Granulosa-stromal cell tumors, theca cell tumors
• Androblastomas
• Gynandroblastomas
• Unclassified
13. III. Lipid cell tumors
IV. Germ cell tumors:
• Dysgerminoma
• Endodermal sinus tumor
• Embryonal ca.
• Polyembryoma
• Choriocarcinoma
• Teratoma
• Mixed
14. V. Gonadoblastomas:
• Pure
• Mixed
VI. Soft tissue tumors (not specific to ovary)
VII. Unclassified tumors
VIII. Secondary tumors
IX. Tumor-like conditions
16. CLINICAL PRESENTATION
• Age
• Parity
• Symptoms
• Signs
• On Examinations
– Abdominal
• Inspection
• Palpation
• Percussion
– Pelvic
Benign ovarian neoplasms are indistinguishable clinically from malignant
counterparts
17. PHYSICAL EXAMINATION
• Abdominal and vaginal examination and the presence
or absence of local lymphadenopathy
• Assess
– Laterality
– Cystic Vs solid
– Mobile Vs fixed
– Smooth Vs irregular
– Ascites
– Cul-de-sac nodules
– Rapid growth rate
21. • Pattern recognition is superior to all other scores.
• Subjective evaluation of ovarian masses based on pattern
recognition can achieve sensitivity of 88% to 100% and
specificity of 62% to 96%.
• Adding doppler does not seem to yield much improvement in
the diagnostic precision, but increases the confidence with
which a correct diagnosis of benignity or malignancy is made.
TVS
22. DOPPLER EVALUATION
• Hypoxic tissue in tumors recruit low-resistance, high-flow blood
vessels
• Role in evaluating ovarian mass is controversial – as the ranges of
values of RI,PI,MSV between benign and malignant masses overlap.
PI<1, RI<0.4
• To overcome this, vascular sampling of suspicious areas (papillary
projections, solid areas, thick septations) using both 3D USG and
power doppler both has been evaluated and found effective.
• “Chaotic” vascular pattern in malignancy
23. OTHER IMAGING MODALITIES
• CT, MRI, PET not recommended in the initial evaluation
• CT scan: evaluating
– LN involvement,
– Omental mets, peritoneal deposits, hepatic mets,
– obstructive uropathy
– or a probable alternate primary site when cancer is suspected based
upon TVS
• MRI : differentiating non adnexal pelvic masses (like leiomyomata),
expensive and inconvenient.
• ACOG GUIDELINES 2007
24. Differences Benign Malignant
1. Age More common in late
child-bearing age
More common in post-
menopausal age
2. Parity No correlation More with nulliparity or
family H/O
3. Symptoms Gradual growth Rapid growth
4. Signs General cond. Uneffected Cachexia & pallor,
jaundice, LN
5. Per abdomen More or less mobile,
commonly cystic, border
defined and smooth
surface
Liver enlarged, firm and
nodular. SOL- solid &
heterogenous with
restricted mobility,
irregular surface with
probable adhesions
Differences
28. SENSITIVITY SPECIFICITY PPV NPV
61-90% 71-93% 35-91% 67-90%
CA-
125
Most useful when non-mucinous epithelial cancers are present
Elevated in 80% of patients with epithelial ovarian Ca but only in 50% of patients
with stage I disease
Increased sensitivity in post menopausal women esp. when associated with
relevant clinical and USG findings
Cut-off of 30 u/ml, sensitivity of 81% and specificity of 75%
29. HE4
• HE4 is a precursor to the epididymal secretory protein E4 and in normal
ovarian tissue, there is minimal gene expression and production of HE4.
• As a single tumor marker, HE4 had the highest sensitivity for detecting
ovarian cancer, especially Stage I disease.
• Combined CA125 and HE4 is a more accurate predictor of malignancy
than either alone or to any other dual combination of markers
• HE4 levels(>70 pM) were found to be elevated in over half of the patients
with ovarian cancer with normal serum CA125 levels (>35 U/ml)
• HE4 when studied in the premenopausal group of patients was able to
discriminate benign tumors from malignancies
Moore et al. / Gynecologic Oncology, 2008
30. NEW SCORES
• ROMA: Risk of Ovarian Malignancy Algorithm
The dual marker algorithm utilizing HE4 and CA125 to calculate a ROMA value
In patients with stage I and II disease, ROMA achieved a sensitivity of 85.3% compared
with 64.7% for RMI
MOORE ET AL, AJOG 2010
• OVA 1:
FDA approved. Combination of 5 immunoassays
CA 125, transthyrettin, apo lipoprotein A1, transferrin, B2 microglobulin
Sensitivity : 93%, specificity: 43% PPV 42% NPV 93%
COMMUN ONCOL, 2010
31. Asymptomatic simple cysts
<5cms Likely physiological
(do not require follow up)
5-7 cms Yearly USG
>7cm Require further
imaging/surgical intervention.
RCOG 2011
32. Ovarian mass in reproductive age group
<5 cms. >/= 5 cms
USG USG
cystic
observation
Complex,
solid,
suspicious
Persistence or progression
surgery
33. Ovarian mass in childhood:
History and physical examination
Appr. Imaging studies
Simple cyst
- Observe and reassess
Solid or solid cystic
MRI and tumor markers
High suspicion
of malignancy
Low suspicion
of malignancy
Laparotomy laparoscopy
Frozen section
Malignant –
oophorectomy
and staging
Benign - cystectomy
34. Ovarian cysts in postmenopausal women:
• Post menopausal gonad atrophies to a size of
1.5 X 1 X 0.5cm on average
• Shouldn’t be palpable on pelvic examination.
• Presence of palpable ovary must alert the
possibility of an underlying malignancy.
35. • Incidence in asymptomatic post menopausal women
–
1.5% by pelvic examination
3.3% to 14.5% by USG.
obstet gynecol survey, 2002
• Causes -10% functional
90% neoplastic (either benign or malignant)
36. ASSESSMENT
• It is recommended that ovarian cysts in postmenopausal women
should be assessed using CA125 and transvaginal grey scale
sonography.
• There is no routine role yet for Doppler, MRI, CT or PET.
RCOG 2010
SENSITIVITY SPECIFICITY
TVS 89% 73%
CA 125 81% 75%
39. RCOG
• Simple, unilateral, unilocular ovarian cysts, less than 5 cm in diameter, have a
low risk of malignancy. It is recommended that, in the presence of a normal
serum CA125 levels, they be managed conservatively.
• Aspiration is not recommended for the management of ovarian cysts in
postmenopausal women.
• It is recommended that a ‘risk of malignancy index’ should be used to select
women for laparoscopic surgery, to be undertaken by a suitably qualified
surgeon.
• It is recommended that laparoscopic management of ovarian cysts in
postmenopausal women should involve oophorectomy (usually bilateral)
rather than cystectomy.
41. They were not separately classified by the FIGO and the WHO
until the early 1970s.
• Borderline tumors make up approximately 15% of all
epithelial ovarian tumors.
• The mean age of occurrence is approximately 10 years
younger than that of women with frankly malignant ovarian
cancer.
42. Tumour subtypes
• 2 major histological tumor subtypes
– Serous(50%)
• (bilateral in 30%)
• Could be associated with extraovarian lesion : implants(35%)
– Mucinous (46%)
• Mucinous tumors do not have a clearly defined origin.
– Substantial information indicates that many tumors may
actually originate from the appendix; thus, this organ
should be removed at the time of surgery.
44. Histology and Cytology
• According to Dietel and Hauptmann, the histology of borderline tumors is
characterized by the following features:
– Epithelial multi-layering of more than 4 cell layers
– Not more than 4 mitoses per 10 high-power field (HPF)
– Mild nuclear atypia
– Increase in nuclear/cytoplasmic ratio
– Slight to complex branching of epithelial papillae and pseudopapillae
– Epithelial budding and cell detachment into the lumen
– No destructive stromal invasion - A major component in
differentiating malignant from borderline tumors
45. TUMOR STAGING
• Comprehensive staging : of significant prognostic
value and is performed surgically
• Borderline ovarian tumors are staged according to
the FIGO classification of ovarian cancer.
46. International Federation Of Obstetrics And Gynecology
(FIGO) staging
FIGO stage Definition
I Tumor confined to the ovary
II Peritoneal implants within the pelvis
III
Peritoneal implants beyond the pelvis,
Positive lymph nodes, or both
IV
Liver parenchyma involvement, or tumor
beyond the peritoneal cavity
49. Summary
Ovarian Mass
Reproductive Age
<45yrs
Peri/Postmenopausal
3-5cm >5-7cm >=7cm
Do
Nothing
Follow-up
MRI or
Surgery
RCOG guidelines-62 &34;2011 & 2010
TVS if not performed & CA-125
Calculate RMI
RMI<25 RMI>25-250 RMI>250
Simple U/L <5cm
& CA-125 <30
Other cyst
F/U with TVS & CA-125
4monthly / 1yr
Laraoscopic
removal
Laparoscopy
or laparotomy
in Cancer unit
Laparotomy
in other Sp.
Centre
Notas del editor
The morphology index (MI) presently used in the University of Kentucky Ovarian Cancer Screening Trial was published initially by Ueland and colleagues and is illustrated in Figure 49.3. Both morphologic complexity and tumor volume, as calculated by the prolate ellipsoid formula, were related directly to the risk of malignancy
Morphologic abnormalities were easy to categorize, and interobserver variation was minimal. Risk of malignancy varied from 0.3% in ovarian tumors with a MI of <5 to 84% in tumors with a MI >=8. Using a MI >=5 as indicative of malignancy, the following statistical parameters were observed: sensitivity 0.981, specificity 0.808, PPV 0.409, and NPV 0.997. Therefore, morphologic indexing is a relatively accurate and cost-effective method to predict risk of malignancy in an ovarian tumor.
Using these rules the reported sensitivity was 95%, specificity 91%, positive
likelihood ratio of 10.37 and negative likelihood ratio of 0.06.
Wenever possible conservative or minimally invasive surgery is preferred to preserve endocrine and reproductive function.
BOTs form a separate entity within the group of ovarian tumours
BOTs can be divided according to their epithelial characteristics as serous (50%),mucinous (46%), and mixed, endometrioid, clear cell, or Brenner tumors (3.9%). Serous BOTs are bilateral in 30% of patients and can be associated with extraovarian lesions (so-called implants) in 35%. These implants can be invasive or noninvasive depending on their microscopic appearance, which will in turn influence therapeutic options. Mucinous BOTs are classified as intestinal (85%) or endocervical/Mullerian type (15%) depending on the nature of the epithelial lining. They can be associated with pseudomyxoma peritonei (10%), necessitating a thorough investigation of the GI tract with special attention to the appendix because this
can be the primary tumor origin.
Presenting symptoms of borderline ovarian tumors
Borderline tumors, as with other ovarian tumors, are difficult to detect clinically until they are advanced in size or stage. In one study, the most common presenting symptoms were abdominal pain, increasing girth or abdominal distention, and abdominal mass. Approximately 23% of patients were asymptomatic.
Without comprehensive surgical staging, the prognosis for an individual patient is difficult to predict.
Many clinicians group stages II-IV together for prognostic consideration.
Important component is description of the type of implants, as these have significant prognostic value.
Preoperatively, borderline tumors are often presumed to be either benign or malignant ovarian masses; however, as with other ovarian masses, staging is performed surgically. Many sources recommend complete staging if a borderline tumor is found. Current guidelines include biopsy specimens of the pelvic peritoneum (cul-de-sac, pelvic wall, and bladder peritoneum), abdominal peritoneum (paracolic gutters and diaphragmatic surfaces), omentum, intestinal serosa and mesentery, and retroperitoneal lymph nodes (pelvic and para-aortic).
Surgical removal of BOTs is the cornerstone in the management of BOTs, but a lot of debate exists on the extent of the staging procedure and the surgical approach. Lately, the use of laparoscopy and conservative surgery, which is defined as surgery with complete staging but with
preservation of the uterus and at least part of one ovary (Fig 1), is gaining popularity. However, the question arises about whether this management is appropriate or whether we should be more cautious.